New IgGNITE study results show 50% lower infusion volume and comparable pharmacokinetic outcomes versus Hyqvia, supporting TAK-881’s potential as a once-monthly facilitated subcutaneous immunoglobulin therapy.
Takeda has announced detailed results from its pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001), evaluating investigational TAK-881 for primary immunodeficiency disease (PID). The findings, presented in two late-breaking posters at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID 2026) in Maastricht, the Netherlands, highlight the therapy’s potential to reduce treatment burden for patients requiring long-term immunoglobulin (IG) replacement therapy.
TAK-881 combines a 20% immunoglobulin subcutaneous solution (SCIG 20%) with recombinant human hyaluronidase. If approved, it could become the first facilitated SCIG 20% therapy for PID designed for administration as infrequently as once every three to four weeks.
Previously reported topline results showed that the trial met its primary endpoint, demonstrating pharmacokinetic (PK) comparability between TAK-881 and Hyqvia, an established immunoglobulin 10% therapy with recombinant human hyaluronidase. The newly presented findings provide further detail on infusion volume, administration time, infection outcomes and safety in participants aged 16 years and older.
Key Findings from the IgGNITE Trial
-
50% lower infusion volume: TAK-881 delivered an equivalent bodyweight-adjusted immunoglobulin dose in half the volume compared with Hyqvia.
-
Up to 42.6% shorter infusion time: Median infusion duration at one infusion site was reduced by 56.2 minutes.
-
Comparable pharmacokinetic outcomes: IgG exposure was comparable between TAK-881 and Hyqvia, with similar descriptive steady-state PK parameters.
-
Protective IgG levels: Median trough IgG concentrations remained above accepted protective thresholds against infections.
-
Comparable safety profile: No new safety signals or TAK-881-related serious adverse events were identified in the reported comparison.
-
Potential for less frequent treatment: TAK-881 is being developed to support dosing every three to four weeks.
Lower Infusion Volume and Shorter Administration Time
For many people living with PID, lifelong immunoglobulin replacement therapy is necessary to help maintain protective antibody levels and prevent infections. However, infusion volumes, administration duration and the frequency of treatment can create substantial practical challenges.
The IgGNITE trial found that TAK-881’s concentrated 20% formulation reduced infusion volume by 50% while delivering an equivalent immunoglobulin dose. This reduction was associated with shorter median infusion durations compared with Hyqvia.
| Infusion measure | TAK-881 | Hyqvia | Difference |
|---|---|---|---|
| Infusion volume | 50% lower | Reference | 50% reduction with TAK-881 |
| Median duration, one infusion site | 75.8 minutes | 132 minutes | 56.2 minutes shorter |
| Median duration, two infusion sites | 58.3 minutes | 86 minutes | 27.7 minutes shorter |
| Median maximum tolerated infusion rate | 300 mL/hour/site | — | — |
The reduction in infusion volume may also allow treatment through fewer infusion sites in some circumstances. These findings suggest that TAK-881 could help reduce the time and practical effort associated with ongoing immunoglobulin therapy.
Pharmacokinetic Comparability and Infection Outcomes
The trial met its primary endpoint by demonstrating equivalent immunoglobulin G (IgG) exposure between TAK-881 and Hyqvia. Descriptive analyses of secondary pharmacokinetic measures were also consistent between the treatments.
Median steady-state trough IgG concentrations, expressed as geometric means, were 11.7 g/L with TAK-881 and 11.9 g/L with Hyqvia. Both values were above accepted protective thresholds against infections.
The study also reported low annualized infection rates and a low annualized serious bacterial infection rate. Overall, the findings supported comparable immune protection based on descriptive analyses, although the reported data should not be interpreted as proof of superiority over Hyqvia.
Safety and Tolerability
TAK-881 was generally well tolerated in the reported comparison, with no new safety signals or TAK-881-related serious adverse events identified.
| Safety measure | TAK-881 | Hyqvia |
|---|---|---|
| Participants experiencing treatment-emergent adverse events (TEAEs) | 56.1% (23/41) | 50.0% (19/38) |
| Severity of reported TEAEs | Mild to moderate | Mild to moderate |
| TAK-881-related Grade 3 or higher TEAEs | None reported | Not applicable |
Across both treatment periods, 9 of 43 randomized participants (20.9%) discontinued the study. No adverse events considered related to TAK-881 led to study discontinuation.
Long-term safety and tolerability continue to be evaluated in the ongoing Phase 3 TAK-881-3002 extension study.
Clinical Trial Design
The pivotal Phase 2/3 IgGNITE trial evaluated the pharmacokinetics, efficacy, safety, tolerability and immunogenicity of TAK-881 in adults and children aged two years and older with PID who had previously received immunoglobulin therapy.
The study included two parts:
-
Participants aged 16 years and older: An open-label, randomized crossover comparison of TAK-881 and Hyqvia, with participants receiving both treatments in different sequences at the same immunoglobulin dose and dosing interval for up to 51 weeks.
-
Participants aged two to under 16 years: An open-label, single-arm cohort receiving TAK-881 for up to 27 weeks.
The detailed results highlighted at ESID 2026 focused on participants aged 16 years and older.
Experts Highlight Potential to Reduce Treatment Burden
Dr. Jolan Walter, MD, PhD, Division Chief of Paediatric Allergy & Immunology at the University of South Florida and Johns Hopkins All Children's Hospital, emphasized the importance of reducing the practical burden of lifelong immunoglobulin replacement.
“Reducing the administrative treatment burden is crucial for patients with primary immunodeficiency who often face lifelong immunoglobulin replacement. By halving infusion volume, the facilitated SCIG 20% meaningfully shortened administration times while maintaining once-monthly dosing – delivering consistent protection while potentially giving patients back time.”
Kristina Allikmets, MD, PhD, Senior Vice President and Head of Plasma Derived Therapies R&D at Takeda, said TAK-881 reflects the company’s efforts to improve the treatment experience for people living with chronic immunodeficiencies.
“Building on the trusted clinical heritage of Hyqvia through insights shaped by our ongoing dialogue with the PID community, TAK-881 reflects our efforts to improve the day-to-day care experience for individuals with chronic immunodeficiencies. If approved, TAK-881 would further strengthen our industry-leading immunoglobulin offering for immunodeficiencies by adding a more convenient administration option anchored in the proven efficacy and safety of our portfolio. We look forward to advancing TAK-881 through regulatory reviews and, if approved, bringing this innovation to patients.”
Regulatory Plans and Next Steps
Takeda expects to submit regulatory applications for TAK-881 in the United States, European Union and Japan during fiscal year 2026.
TAK-881 remains investigational and has not been approved for use. The ongoing extension study will contribute additional evidence on its long-term safety and tolerability.
About Primary Immunodeficiency Disease
Primary immunodeficiency disease comprises more than 550 rare, chronic disorders in which part of the immune system is missing or does not function properly. These conditions are commonly associated with genetic mutations and can lead to frequent or persistent infections and other immune-related complications. Diagnosis may be delayed because symptoms vary and can overlap with those of other conditions.
Immunoglobulin replacement therapy provides antibodies collected from human plasma to help maintain immune protection in eligible patients.
About Takeda
Takeda is a global biopharmaceutical company focused on discovering and delivering treatments across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. The company works with partners to improve patient experiences and advance treatment options through its research and development pipeline.
Conclusion
The IgGNITE trial results indicate that investigational TAK-881 may offer a less burdensome approach to subcutaneous immunoglobulin replacement for people with PID. By reducing infusion volume by 50% and shortening median infusion time by up to 42.6% at one site, while demonstrating comparable pharmacokinetic outcomes and a consistent reported safety profile versus Hyqvia, TAK-881 could become a potential future treatment option if regulatory authorities approve it.
